Get the Stockscreener App
6.27
8.87%
-0.61
After Hours:
6.38
0.11
+1.75%
Capricor Therapeutics Inc stock is traded at $6.27, with a volume of 3.51M.
It is down -8.87% in the last 24 hours and down -24.09% over the past month.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
See More
Previous Close:
$6.88
Open:
$6.9
24h Volume:
3.51M
Relative Volume:
1.20
Market Cap:
$286.39M
Revenue:
$27.10M
Net Income/Loss:
$-24.31M
P/E Ratio:
-7.5542
EPS:
-0.83
Net Cash Flow:
$-33.33M
1W Performance:
-15.10%
1M Performance:
-24.09%
6M Performance:
-55.41%
1Y Performance:
+33.69%
1-Day Range:
$6.19
$6.966
1-Week Range:
$6.19
$7.46
52-Week Range:
$3.52
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
Compare CAPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
6.27 | 337.55M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Initiated | Alliance Global Partners | Buy |
| Jun-26-25 | Initiated | B. Riley Securities | Buy |
| May-20-25 | Initiated | Roth Capital | Buy |
| Oct-21-24 | Initiated | Piper Sandler | Overweight |
| May-17-24 | Initiated | Oppenheimer | Outperform |
| Jan-05-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
What drives Capricor Therapeutics Inc. stock priceFree Trading Psychology Coaching - Autocar Professional
Capricor Therapeutics Inc. Stock Analysis and ForecastFree Advanced Stock Screener Access - Autocar Professional
CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Capricor Therapeutics, Inc. Investors of Upcoming Deadline - ACCESS Newswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
(CAPR) Technical Data - news.stocktradersdaily.com
Securities Fraud and Market Volatility in Biotech: Lessons from Capricor's Downfall - AInvest
Rosen Law Firm Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
Investors Urged to Contact Levi & Korsinsky for Information Before September 15, 2025Capricor Therapeutics, Inc. (CAPR) - TradingView
Capricor Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before September 15, 2025 to Discuss Your Rights – CAPR - GlobeNewswire
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - WV News
Important Notice to Long-Term Shareholders of Capricor - GlobeNewswire
Shareholders that lost money on Capricor Therapeutics, Inc.(CAPR) Urged to Join Class ActionContact The Gross Law Firm to Learn More - PR Newswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - WV News
Class Action Lawsuit Filed: Capricor Therapeutics, Inc. (CAPR)Join by September 15, 2025Contact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Notifies Capricor Therapeutics, Inc. (CAPR) Shareholders of Class Action Lawsuit and September 15, 2025 Deadline - ACCESS Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - StreetInsider
CAPR ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Capricor Therapeutics, Inc.September 15, 2025 Deadline - ACCESS Newswire
What analysts say about Capricor Therapeutics Inc. stockTremendous return on equity - PrintWeekIndia
Is Capricor Therapeutics Inc. a good long term investmentRapid capital growth - jammulinksnews.com
CAPRICOR ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire
CAPRICOR ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) INVESTOR ALERT: - GlobeNewswire
Investor Sues Biotech Capricor After Product's FDA Denial - Law360
Levi & Korsinsky Urges Capricor Therapeutics, Inc. (CAPR) Shareholders to Act Before Lead Plaintiff Deadline September 15, 2025 - ACCESS Newswire
Capricor Investor Sues After Disappointing FDA Return on Therapy - Bloomberg Law News
Join Class Action to Recover Losses from Capricor Therapeutics, Inc. (CAPR)Contact Levi & Korsinsky Before September 15, 2025 - TradingView
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Will Capricor Therapeutics Inc. stock split in the near futureInvestor Favorite Picks - Newser
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - GlobeNewswire
CAPR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Capricor Therapeutics, Inc. Investors - TradingView
Capricor’s Trial Data Deception Triggers Major Lawsuit - TipRanks
What analysts say about Capricor Therapeutics Inc. stock outlookPrecision Entry Strategy - Newser
Shareholders Filed a Lawsuit Against Capricor for Misleading Investors About FDA Approval - TradingView
Capricor Therapeutics ($CAPR) Regulatory Misrepresentations and Stock Collapse Case - TradingView
BREAKING: Capricor Therapeutics Sued For Securities Fraud; - GlobeNewswire
September 15, 2025 Deadline Approaching: Join Class Action Against Capricor Therapeutics, Inc. (CAPR)Contact Levi & Korsinsky - ACCESS Newswire
Shareholder Alert: Robbins LLP Informs Investors of the Capricor Therapeutics, Inc. Class Action - GlobeNewswire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - PR Newswire
Roth Capital Issues Pessimistic Forecast for CAPR Earnings - Defense World
Equities Analysts Offer Predictions for CAPR FY2025 Earnings - Defense World
Investigation Opened on Behalf of Capricor Therapeutics, Inc. (CAPR) ShareholdersContact Levi & Korsinsky - ACCESS Newswire
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives $24.67 Consensus PT from Brokerages - Defense World
Bragar Eagel & Squire, P.C. is Investigating Capricor - GlobeNewswire
Roth Capital Lowers Capricor Therapeutics (NASDAQ:CAPR) Price Target to $12.00 - MarketBeat
Lost Money on Capricor Therapeutics, Inc. (CAPR)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Capricor Sinks After FDA Rejects Drug for Muscle Disease - MSN
How Capricor Therapeutics Inc. stock performs during market volatilityFree Access to Stock Community - Newser
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.87%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):